Skip to main content

Table 4 Univariate and multivariate cox proportional hazard model for the survival of breast cancer patients

From: Aberrant PTPRO methylation in tumor tissues as a potential biomarker that predicts clinical outcomes in breast cancer patients

Variable Univariate analysis Multivariate analysis
  Hazard ratio 95% CI P Hazard ratio 95% CI P
Tumor size (large vs small) 2.4 1.2-4.9 0.019    
Lymph node status (pos. vs neg.) 4.9 2.4-9.8 0.0001 4.0 1.6 - 9.9 0.003
Histological grade (poor vs well) 2.1 1.1-4.0 0.033    
Stage (III vs I/II) 3.2 1.7-5.9 0.0001    
HER2 status (amp. vs wildtype) 2.2 1.1-4.2 0.022    
TP53 (mutant vs wildtype) 2.3 1.2-4.3 0.012    
Tumor tissue PTPRO methylation (yes vs no) 3.8 1.9-7.5 0.0001 2.7 1.1- 6.2 0.023
ER + group tumor tissue PTPRO methylation (yes vs no) 3.9 1.7-8.7 0.001 2.8 1.0-8.4 0.060
PR + group tumor tissue PTPRO methylation (yes vs no) 3.1 1.2-7.4 0.012 3.2 0.8-11.9 0.091
HER2+ group tumor tissue PTPRO methylation (yes vs no) 5.0 1.8-16.8 0.010 7.5 1.8-31.3 0.006
\